Infliximab treatment in psoriatic arthritis: our experience.
Acta Biomed
; 77(2): 95-102, 2006 Aug.
Article
en En
| MEDLINE
| ID: mdl-17172189
ABSTRACT
The aim of this work was to give clinical practice recommendations on the use of tumour necrosis factor blocking agents in psoriatic arthritis, underlining the pathogenetic mechanism of this condition and its articular and dermatologic manifestations. We retrace the stages leading to the therapeutic indications of biological agents that are presently used in the treatment of psoriatic arthritis Entanercept, Adalimumab, Infliximab. We also report our personal experience describing an emblematic case of a patient with psoriatic arthritis in which a decisive regression of joint/skin involvement was obtained with Infliximab treatment.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Artritis Psoriásica
/
Factor de Necrosis Tumoral alfa
/
Antirreumáticos
/
Fármacos Dermatológicos
/
Antiinflamatorios
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Acta Biomed
Asunto de la revista:
MEDICINA
Año:
2006
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
IT
/
ITALIA
/
ITALY
/
ITÁLIA